AKT1 and lung carcinoma: In recent years, emerging genes have been revealed to be the potential therapeutic targets of lung cancer by inhibiting the PI3K/AKT/mTOR pathway, such as SREBP [25], DOK7V1 [26], HRH3 [27], SLFN5 [28], and FABP5 [29].